• To determine clinical activity and safety of bevacizumab when combined with ABVD for primary therapy of Hodgkin lymphoma [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  

• To evaluate effect of therapy on circulating angiogenic factors and correlate with tissue expression of VEGF and receptors. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  

Drug: Avastin
Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.

Participants will be given Avastin as well as ABVD (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) intravenously on days 1 and 15 of a 28 day cycle. Participants will receive up to a total of 6 cycles of therapy.

Inclusion Criteria:

• 18 years of age or older
• Biopsy proven classical Hodgkin lymphoma. Classical Hodgkin lymphoma includes the subtypes of nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted, and classical Hodgkin lymphoma unspecified
• Advanced stage (Stage III or IV) disease
• Measurable disease on cross sectional imaging
• ECOG Performance Status 0-2
• Adequate blood counts and organ function

Exclusion Criteria:

• Pregnant or lactating women
• Laboratory Parameters as outlined in the protocol
• LV ejection fraction lower than normal as assessed by echocardiogram or MUGA scan
• DLCO less than 60% as measured by pulmonary function tests
• Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for over one year
• Current or recent (within 4 weeks of the first infusion of this study) participation in an experimental drug study
• Life expectancy of less than 12 weeks
• Inability to comply with study procedures
• Inability to give informed consent
• Inadequately controlled hypertension
• Any prior history of hypertensive crisis or hypertensive encephalopathy
• NYHA Grade II or greater congestive heart failure
• History of myocardial infarction or unstable angina within 6 months prior to study enrollment
• History of stroke or transient ischemic attack within 6 months prior to study enrollment
• Known CNS involvement of Hodgkin lymphoma
• Significant vascular disease
• Symptomatic peripheral vascular disease
• Evidence of bleeding diatheses or coagulopathy
• Use of daily anticoagulant medications including warfarin, heparins, or aspirin >325mg daily
• Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
• Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days of study enrollment
• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
• Serious, non-healing wound, ulcer, or bone fracture
• Proteinuria at screening
• Known hypersensitivity to any component of bevacizumab
• Pregnant or lactating